<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277875</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0217</org_study_id>
    <nct_id>NCT00277875</nct_id>
  </id_info>
  <brief_title>STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH</brief_title>
  <official_title>The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synvista Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Synvista Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine whether increasing arterial distensibility by decreasing advanced glycation&#xD;
      end-product (AGE) cross-link components of vascular stiffness improves (a)&#xD;
      endothelial-mediated vasoreactivity at rest, as assessed by flow-mediated vasodilation (FMD),&#xD;
      and (b) endothelial-mediated vasoreactivity after exercise, as assessed by pulse&#xD;
      perfusion-mediated vasodilation (PPMV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Explore several independent variables as potential independent predictors of vascular&#xD;
           stiffness and endothelial function. These parameters include patient age, body mass&#xD;
           index, gender, renal disease, history of cardiovascular disease, serum cholesterol, and&#xD;
           antihypertensive medication use.&#xD;
&#xD;
        -  Provide insight into nitric oxide-dependent endothelial function in the setting of&#xD;
           increased arterial stiffness by determination of substances in the nitric oxide&#xD;
           signaling pathway (specifically, levels of serum cGMP; serum nitrate and nitrite; and&#xD;
           serum asymmetric dimethylarginine [ADMA], an endogenous inhibitor of nitric oxide&#xD;
           synthase).&#xD;
&#xD;
        -  Provide insight into changes in AGE levels and collagen metabolism in response to&#xD;
           alagebrium therapy [specifically, AGEs: pentosidine, carboxymethyllysine,&#xD;
           carboxyethyllysine, furosine; Collagen markers: procollagen I carboxyterminal propeptide&#xD;
           (PICP), procollagen type I N terminal propeptide (PINP), cross-linked carboxyterminal&#xD;
           telopeptide of Type I collagen (ICTP), n-terminal propeptide of type III procollagen&#xD;
           (PIIINP)].&#xD;
&#xD;
        -  Provide insight into changes in markers of inflammation in response to alagebrium&#xD;
           therapy [specifically, free and total serum matrix metalloproteinase-1(MMP-1), free&#xD;
           tissue inhibitor of metalloproteinase 1 (TIMP1), intercellular adhesion molecule-1&#xD;
           (ICAM), P-selectin, von Willebrand factor (vWf), interleukin-6 (IL-6), and&#xD;
           high-sensitivity C reactive protein (hs CRP)].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local distensibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial stiffening</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Augmentation index (AI)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of endothelial function, vascular inflammation and collagen synthesis.</measure>
  </primary_outcome>
  <enrollment>25</enrollment>
  <condition>Cardiovascular Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-711 (alagebrium chloride)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 50 years of age or greater.&#xD;
&#xD;
          2. Diagnosed with systolic hypertension (systolic blood pressure &gt;140 mm Hg and (less&#xD;
             than or equal to) 200 mm Hg, and a diastolic blood pressure (less than or equal to) 95&#xD;
             mm Hg) and elevated pulse pressure (systolic blood pressure [SBP] minus diastolic&#xD;
             blood pressure [DBP] greater than 60 mm Hg).&#xD;
&#xD;
          3. Normal left ventricular function (ejection fraction &gt;55%) at baseline (Visit 3).&#xD;
&#xD;
          4. Able to perform bicycle exercise.&#xD;
&#xD;
          5. Able to read, understand and sign the informed consent after the nature of the study&#xD;
             has been explained.&#xD;
&#xD;
          6. If sexually active, the patient agrees to use reliable contraception while&#xD;
             participating in this study. If a woman, is surgically sterilized or post-menopausal,&#xD;
             or has a negative serum pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Aortic stenosis, prior known coronary artery disease (including myocardial&#xD;
             infarction), cerebrovascular accident, or peripheral vascular disease.&#xD;
&#xD;
          2. Uncontrolled hypertension (SBP &gt; 200/ DBP &gt; 95 mm Hg).&#xD;
&#xD;
          3. Atrial fibrillation, diabetes mellitus treated with insulin, or chronic lung disease.&#xD;
&#xD;
          4. Any additional condition(s) which, in the opinion of the investigator, would prohibit&#xD;
             the patient from completing the study, or not be in the best interest of the patient.&#xD;
&#xD;
          5. Treatment with nitrates, or a change in antihypertensive medications within the last 1&#xD;
             month.&#xD;
&#xD;
          6. Treatment with any investigational drug within 1 month prior to study drug&#xD;
             administration.&#xD;
&#xD;
          7. Previous exposure to alagebrium.&#xD;
&#xD;
          8. AST (SGOT) or ALT (SGPT) &gt; 2x normal limit.&#xD;
&#xD;
          9. Serum creatinine &gt; 2.0 ng/mL.&#xD;
&#xD;
         10. Cigar/cigarette smoking.&#xD;
&#xD;
         11. Necessity to use smokeless tobacco or nicotine-containing products, or to consume&#xD;
             caffeine, alcohol, or antioxidants starting at midnight prior to study clinic visits.&#xD;
             NOTE: Water is allowed ad libitim.&#xD;
&#xD;
         12. Positive drug screen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Zieman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001 Sep 25;104(13):1464-70.</citation>
    <PMID>11571237</PMID>
  </reference>
  <reference>
    <citation>Liu ZR, Ting CT, Zhu SX, Yin FC. Aortic compliance in human hypertension. Hypertension. 1989 Aug;14(2):129-36.</citation>
    <PMID>2759675</PMID>
  </reference>
  <reference>
    <citation>Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. Erratum in: J Am Coll Cardiol 2002 Mar 20;39(6):1082.</citation>
    <PMID>11788217</PMID>
  </reference>
  <reference>
    <citation>Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin Cardiol. 1999 Nov;22(11):705-10.</citation>
    <PMID>10554684</PMID>
  </reference>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>January 13, 2006</study_first_submitted>
  <study_first_submitted_qc>January 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <keyword>Cardiovascular</keyword>
  <keyword>Flow-Mediated Vasodilation (FMD)</keyword>
  <keyword>Pulse Perfusion-Mediated Vasodilation (PPMV)</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Local Distensibility</keyword>
  <keyword>Arterial Stiffening</keyword>
  <keyword>Augmentation Index (AI)</keyword>
  <keyword>Aging</keyword>
  <keyword>Isolated Systolic Hypertension</keyword>
  <keyword>Advanced Glycation Endproducts</keyword>
  <keyword>Vascular Stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

